TDA may have a different list but what I have been following
|
Column 1 |
Column 2 |
Column 3 |
1 |
Development Name |
Type |
Indication |
2 |
SAR339658 |
Anti-VLA 2 mAb |
Multiple Sclerosis |
3 |
SAR228810 |
Anti-protofibrillar AB mAb |
Alzheimer’s disease |
4 |
SAR252067 |
Anti-LIGHT mAb |
Crohn’s disease |
5 |
Alirocumab |
PCSK9 mAb |
Cholesterol |
6 |
SAR113244 |
Anti-CXCRS mAb |
Systemic lupus erythematosu |
7 |
Dupilumab |
IL4RαmAbAtopic |
Dermatitis; Asthma; Nasal polyposis
|
Dupilumab has 3 target indications so you could almost count that as three. Though best leave it at one until you see some dosages for later stage trials being over 300mg which is not a bad rule of thumb cut off point for viscosity/volume/concentration exceeding PFS and AIDs capability
First cab off the rank is hopefully Alirocumab and Sanofi-REGN chasing Amgen and monthly dosing (Awaits reporting on Choice 1 program) Then its Dupilumab by my ruler
Guess with this in the bag UNS may let the cat out of the bag re Sanofi using Finesse for some of the drugs with as Sarilumab, Alirocumab etc. As you point out kar18na the announcement points a finger towards REGN
Good work to those loyal folk who hung around.